Abstract: A drug delivery device having an intraluminal stent for improving coronary luminal diameter of small vessels in patients with symptomatic heart disease is disclosed. The intraluminal stent includes struts having a thickness of less than approximately 110 ?m. A polymer is adhered to the intraluminal stent that includes from about 50 ?g/cm2 to about 150 ?g/cm2 of everolimus therein. Quantitative coronary angiography measurements indicate that the drug delivery device provides an in-stent late loss of less than about 0.20 mm and an in-stent diameter stenosis of less than about 15% at 12 months following implantation in a human.

Abstract: A drug delivery device comprising an intraluminal stent for improving coronary luminal diameter of small vessels in patients with symptomatic heart disease is disclosed. The intraluminal stent comprises struts having a thickness of less than approximately 110 ?m. A polymer is adhered to the intraluminal stent that includes from about 50 ?g/cm2 to about 150 ?g/cm2 of everolimus therein. Quantitative coronary angiography measurements indicate that the drug delivery device provides an in-stent late loss of less than about 0.20 mm and an in-stent diameter stenosis of less than about 15% at 12 months following implantation in a human.